NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical & Diagnostic Laboratories
- Sub-Industry: N/A
- Symbol: NASDAQ:NEO
- CUSIP: N/A
- Web: www.neogenomics.com
Capitalization:- Market Cap: $741.48 million
- Outstanding Shares: 79,388,000
Average Prices:- 50 Day Moving Avg: $9.16
- 200 Day Moving Avg: $8.23
- 52 Week Range: $6.90 - $9.93
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 48.89
- P/E Growth: 2.59
Sales & Book Value:- Annual Revenue: $249.02 million
- Price / Sales: 2.96
- Book Value: $2.13 per share
- Price / Book: 4.36
Profitability:- EBIDTA: $26.72 million
- Net Margins: -2.81%
- Return on Equity: 6.09%
- Return on Assets: 3.11%
Debt:- Debt-to-Equity Ratio: 0.60%
- Current Ratio: 2.37%
- Quick Ratio: 2.21%
Misc:- Average Volume: 309,545 shs.
- Beta: 1.05
- Short Ratio: 19.2
Frequently Asked Questions for NeoGenomics (NASDAQ:NEO)
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, July, 25th. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.03. The firm earned $66.09 million during the quarter, compared to analyst estimates of $62.95 million. NeoGenomics had a negative net margin of 2.81% and a positive return on equity of 6.09%. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.04 earnings per share. View NeoGenomics' Earnings History.
When will NeoGenomics make its next earnings announcement?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share guidance of $0.17-0.21 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.18. The company issued revenue guidance of $255-265 million, compared to the consensus revenue estimate of $258.23 million.
Where is NeoGenomics' stock going? Where will NeoGenomics' stock price be in 2017?
5 equities research analysts have issued 12 month price targets for NeoGenomics' stock. Their forecasts range from $10.00 to $11.00. On average, they expect NeoGenomics' share price to reach $10.75 in the next twelve months. View Analyst Ratings for NeoGenomics.
What are analysts saying about NeoGenomics stock?
Here are some recent quotes from research analysts about NeoGenomics stock:
- 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (7/29/2017)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating and $11 price target following last week's meeting with management. The company highlighted the strategic benefits of its tech-only offering, the Clarient acquisition, positive secular trends that are driving cancer diagnostics, and NEO's strong management team. The biggest takeaway, in our view, was that the Clarient integration continues to progress, which should drive further cost synergies as well as revenue synergies. We estimate that there is a $10-16M low-hanging revenue opportunity from targeting 100 Clarient accounts. We believe that the company will be able to unlock 25-40% of these and, thus, we are modeling $4-6M of revenue synergies ($2-3M in EBITDA contribution), with significant potential upside." (3/22/2017)
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Theravance Biopharma (TBPH), Healthways (TVTY), Emergent Biosolutions (EBS), Foundation Medicine (FMI), CONMED Corporation (CNMD), Innoviva (INVA), Acceleron Pharma (XLRN), USANA Health Sciences (USNA), Impax Laboratories (IPXL), Tenet Healthcare Corporation (THC), Glaukos Corporation (GKOS), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Medpace Holdings (MEDP), OraSure Technologies (OSUR), Momenta Pharmaceuticals (MNTA), BioTelemetry (BEAT) and MyoKardia (MYOK).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Douglas M. VanOort, Chairman of the Board, Chief Executive Officer
- George A. Cardoza, Chief Financial Officer
- Robert J. Shovlin, Chief Operating Officer
- Steven C. Jones, Executive Vice President - Finance, Chief Compliance Officer, Director
- Edwin F. Weidig III, CPA, Principal Accounting Officer, Vice President - Finance
- Steven A. Ross, Chief Information Officer
- Steven G. Brodie Ph.d., Vice President - Operations
- Jennifer Balliet, Vice President - Human Resources
- Sally Agersborg M.D. Ph.D., Director of Hematopathology and Medical Director
- Maher Albitar M.D., Chief Medical Officer, Director - Research and Development
Who owns NeoGenomics stock?
NeoGenomics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include General Electric Co. (18.93%), Vanguard Group Inc. (3.44%), First Light Asset Management LLC (3.37%), Artisan Partners Limited Partnership (2.98%), Janus Henderson Group PLC (2.90%) and Russell Investments Group Ltd. (2.52%). Company insiders that own NeoGenomics stock include Alison L Hannah, Bruce K Crowther, George Cardoza, Jennifer Balliet, Lynn A Tetrault, Maher Albitar, Oort Douglas M Van, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Who sold NeoGenomics stock? Who is selling NeoGenomics stock?
NeoGenomics' stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Uniplan Investment Counsel Inc., Wells Fargo & Company MN, Icon Advisers Inc. Co., Artisan Partners Limited Partnership, Kopp Investment Advisors LLC, Emerald Advisers Inc. PA and Swiss National Bank. Company insiders that have sold NeoGenomics stock in the last year include Jennifer Balliet, Maher Albitar, Steven A Ross and Steven G Brodie. View Insider Buying and Selling for NeoGenomics.
Who bought NeoGenomics stock? Who is buying NeoGenomics stock?
NeoGenomics' stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Falcon Point Capital LLC, Russell Investments Group Ltd., Granite Investment Partners LLC, Northpointe Capital LLC, Royce & Associates LP, Strs Ohio and Rice Hall James & Associates LLC. Company insiders that have bought NeoGenomics stock in the last two years include Alison L Hannah, Bruce K Crowther, Lynn A Tetrault and Robert J Shovlin. View Insider Buying and Selling for NeoGenomics.
How do I buy NeoGenomics stock?
Shares of NeoGenomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NeoGenomics stock can currently be purchased for approximately $9.29.
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for NeoGenomics (NASDAQ:NEO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.60) |
| Consensus Price Target: | $10.75 (15.72% upside) |
Analysts' Ratings History for NeoGenomics (NASDAQ:NEO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/28/2017 | BTIG Research | Reiterated Rating | Buy | $11.00 | Low |  |
| 5/27/2017 | Cantor Fitzgerald | Set Price Target | Buy | $11.00 | N/A | |
| 11/16/2016 | Axiom Securities | Reiterated Rating | Hold -> Sell | | N/A | |
| 10/3/2016 | First Analysis | Initiated Coverage | Overweight | $11.00 | N/A | |
| 9/8/2016 | Raymond James Financial, Inc. | Initiated Coverage | Outperform | $10.00 | N/A | |
| 7/27/2016 | Benchmark Co. | Boost Price Target | Buy | $10.00 -> $12.00 | N/A | |
| 7/9/2016 | Craig Hallum | Reiterated Rating | Buy | | N/A | |
| 5/11/2016 | Roth Capital | Initiated Coverage | Buy | $10.00 | N/A | |
| 1/7/2016 | Janney Montgomery Scott | Initiated Coverage | Buy | $11.00 | N/A | |
| 10/26/2015 | William Blair | Reiterated Rating | Buy | | N/A | |
(Data available from 8/16/2015 forward)
Earnings History for NeoGenomics (NASDAQ:NEO)Earnings History by Quarter for NeoGenomics (NASDAQ NEO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2017 | | $0.05 | | | | | N/A | |
| 7/25/2017 | Q2 2017 | $0.01 | $0.04 | $62.95 million | $66.09 million | View | N/A | |
| 4/26/2017 | Q1 2017 | $0.01 | $0.03 | $61.26 million | $61.68 million | View | N/A | |
| 2/22/2017 | Q416 | $0.03 | $0.05 | $61.83 million | $60.50 million | View | Listen | |
| 10/26/2016 | Q316 | $0.03 | $0.04 | $61.00 million | $60.76 million | View | Listen | |
| 7/26/2016 | Q216 | $0.03 | $0.04 | $61.07 million | $63.10 million | View | Listen | |
| 4/27/2016 | Q116 | ($0.07) | $0.03 | $57.00 million | $59.70 million | View | Listen | |
| 3/1/2016 | Q415 | $0.02 | ($0.03) | $26.46 million | $27.30 million | View | N/A | |
| 4/28/2015 | Q115 | ($0.02) | ($0.01) | $23.36 million | $23.00 million | View | N/A | |
| 2/24/2015 | Q414 | $0.01 | $0.02 | $24.30 million | $25.00 million | View | N/A | |
| 10/30/2014 | Q314 | ($0.01) | $0.01 | $22.43 million | $23.20 million | View | N/A | |
| 7/17/2014 | Q214 | $0.01 | $0.01 | $19.84 million | $20.70 million | View | N/A | |
| 2/19/2014 | Q413 | $0.02 | $0.04 | $17.80 million | $18.30 million | View | N/A | |
| 10/23/2013 | Q313 | $0.01 | $0.02 | $16.84 million | $16.90 million | View | N/A | |
| 7/31/2013 | Q2 2013 | | $0.01 | $16.20 million | $15.60 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for NeoGenomics (NASDAQ:NEO)Current Year EPS Consensus Estimate: $0.11 EPS
Next Year EPS Consensus Estimate: $0.19 EPS
Dividend History for NeoGenomics (NASDAQ:NEO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for NeoGenomics (NASDAQ:NEO)Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 82.56%
Insider Trades by Quarter for NeoGenomics (NASDAQ:NEO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/27/2017 | Alison L Hannah | Director | Buy | 20,000 | $9.19 | $183,800.00 | |
| 6/22/2017 | Jennifer Balliet | VP | Sell | 10,723 | $8.49 | $91,038.27 | |
| 6/5/2017 | Steven A Ross | Insider | Sell | 70,833 | $7.76 | $549,664.08 | |
| 5/26/2017 | Jennifer Balliet | VP | Sell | 3,334 | $7.50 | $25,005.00 | |
| 3/20/2017 | Steven G Brodie | Insider | Sell | 50,000 | $7.93 | $396,500.00 | |
| 9/23/2016 | Maher Albitar | Insider | Sell | 2,800 | $8.40 | $23,520.00 | |
| 9/20/2016 | Maher Albitar | Insider | Sell | 105,300 | $8.20 | $863,460.00 | |
| 9/12/2016 | Maher Albitar | Insider | Sell | 60,075 | $8.23 | $494,417.25 | |
| 8/19/2016 | Maher Albitar | Insider | Sell | 370,000 | $8.23 | $3,045,100.00 | |
| 5/27/2016 | Oort Douglas M Van | CEO | Sell | 481,387 | $8.73 | $4,202,508.51 | |
| 5/18/2016 | Steven A Ross | Insider | Sell | 18,000 | $8.50 | $153,000.00 | |
| 5/9/2016 | Steven A Ross | Insider | Sell | 15,000 | $8.22 | $123,300.00 | |
| 5/2/2016 | Steven C Jones | VP | Sell | 177,745 | $8.21 | $1,459,286.45 | |
| 4/29/2016 | Steven A Ross | Insider | Sell | 112,500 | $8.11 | $912,375.00 | |
| 3/11/2016 | George Cardoza | CFO | Sell | 32,000 | $6.83 | $218,560.00 | |
| 3/9/2016 | Oort Douglas M Van | CEO | Sell | 450,000 | $7.10 | $3,195,000.00 | |
| 3/3/2016 | Alison L Hannah | Director | Buy | 10,000 | $6.90 | $69,000.00 | |
| 12/7/2015 | Lynn A Tetrault | Director | Buy | 3,500 | $7.72 | $27,020.00 | |
| 12/3/2015 | Robert J Shovlin | COO | Buy | 6,550 | $7.75 | $50,762.50 | |
| 11/27/2015 | Steven C Jones | VP | Sell | 385,000 | $8.09 | $3,114,650.00 | |
| 11/2/2015 | Bruce K Crowther | Director | Buy | 6,400 | $7.81 | $49,984.00 | |
| 12/19/2014 | Robert H Horel | VP | Sell | 32,389 | $4.21 | $136,357.69 | |
| 12/18/2014 | Robert H Horel | VP | Sell | 62,893 | $4.20 | $264,150.60 | |
| 12/4/2014 | Michael T Dent | Director | Sell | 11,800 | $4.50 | $53,100.00 | |
| 11/26/2014 | George Cardoza | CFO | Sell | 60,000 | $4.28 | $256,800.00 | |
| 11/21/2014 | Michael T Dent | Director | Sell | 33,200 | $4.51 | $149,732.00 | |
| 5/22/2014 | Robert P Gasparini | Insider | Sell | 100,000 | $3.49 | $349,000.00 | |
| 5/19/2014 | Robert Gasparini | Insider | Sell | 10,000 | $3.65 | $36,500.00 | |
| 3/28/2014 | Maher Albitar | Insider | Buy | 14,492 | $3.51 | $50,866.92 | |
| 3/5/2014 | Michael T Dent | Director | Sell | 300,000 | $3.00 | $900,000.00 | |
| 12/11/2013 | Robert P Gasparini | Insider | Sell | 20,100 | $3.70 | $74,370.00 | |
| 12/9/2013 | George Cardoza | CFO | Sell | 20,000 | $3.66 | $73,200.00 | |
| 12/5/2013 | Robert P Gasparini | Insider | Sell | 32,996 | $3.67 | $121,095.32 | |
| 12/3/2013 | Robert P Gasparini | Insider | Sell | 32,146 | $3.67 | $117,975.82 | |
| 11/25/2013 | Steven C Jones | VP | Sell | 112,969 | $3.58 | $404,429.02 | |
| 4/30/2013 | Steven C Jones | Director | Sell | 100,000 | $3.71 | $371,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for NeoGenomics (NASDAQ:NEO)
Latest Headlines for NeoGenomics (NASDAQ:NEO)
| Source: |
|
| Date | Headline |
|---|
 | NeoGenomics, Inc. (NEO) Upgraded at ValuEngine
www.americanbankingnews.com - August 7 at 11:14 PM |
| NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - August 5 at 12:40 AM |
| Financial Review: NeoGenomics (NEO) & RadNet (RDNT)
www.americanbankingnews.com - August 4 at 12:18 AM |
| $0.03 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter
www.americanbankingnews.com - August 1 at 10:26 PM |
| Head to Head Review: NeoGenomics (NASDAQ:NEO) versus RadNet (RDNT)
www.americanbankingnews.com - August 1 at 4:32 PM |
| NeoGenomics, Inc. (NEO) Director Alison L. Hannah Purchases 20,000 Shares
www.americanbankingnews.com - July 31 at 7:44 PM |
| NeoGenomics, Inc. (NEO) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - July 29 at 2:19 PM |
| NeoGenomics, Inc. (NEO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - July 29 at 9:04 AM |
| RadNet (RDNT) vs. NeoGenomics (NEO) Head to Head Contrast
www.americanbankingnews.com - July 28 at 2:31 PM |
 | Edited Transcript of NEO earnings conference call or presentation 25-Jul-17 2:00pm GMT
finance.yahoo.com - July 28 at 6:04 AM |
 | BRIEF-Neogenomics Inc Q2 revenue $66.1 million
www.reuters.com - July 26 at 4:00 AM |
| NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017
finance.yahoo.com - July 26 at 4:00 AM |
| Investor Network: NeoGenomics, Inc. to Host Earnings Call
finance.yahoo.com - July 26 at 4:00 AM |
| NeoGenomics reports 2Q loss
finance.yahoo.com - July 26 at 4:00 AM |
| NeoGenomics, Inc. (NEO) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - July 25 at 10:08 AM |
| NeoGenomics, Inc. (NEO) Updates FY17 Earnings Guidance
www.americanbankingnews.com - July 25 at 10:08 AM |
| Investor Network Invites You to the NeoGenomics Second Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, July 25, 2017
finance.yahoo.com - July 25 at 6:04 AM |
| Contrasting RadNet (RDNT) and NeoGenomics (NASDAQ:NEO)
www.americanbankingnews.com - July 15 at 7:46 AM |
| Analysts Expect NeoGenomics, Inc. (NASDAQ:NEO) Will Announce Quarterly Sales of $63.06 Million
www.americanbankingnews.com - July 12 at 10:32 AM |
| NeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 12:40 AM |
| NeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.01 Per Share
www.americanbankingnews.com - July 10 at 4:26 PM |
 | Form 4 NEOGENOMICS INC For: Jul 05 Filed by: BRODIE STEVEN G.
www.streetinsider.com - July 7 at 1:46 AM |
| ETFs with exposure to NeoGenomics, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 12:23 AM |
| NeoGenomics Schedules its Q2 2017 Earnings Release for July 25, 2017
finance.yahoo.com - June 28 at 11:39 AM |
| NeoGenomics, Inc. (NEO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - June 27 at 7:24 AM |
| Jennifer Balliet Sells 10,723 Shares of NeoGenomics, Inc. (NEO) Stock
www.americanbankingnews.com - June 26 at 7:38 PM |
| Contrasting NeoGenomics (NEO) and Enzo Biochem (ENZ)
www.americanbankingnews.com - June 26 at 8:16 AM |
 | FDA Approves First Companion Diagnostic Test to Simultaneously Screen for Multiple Non-Small Cell Lung Cancer Therapies
www.prnewswire.com - June 24 at 5:24 AM |
| NeoGenomics, Inc. (NEO) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - June 24 at 12:06 AM |
| ETFs with exposure to NeoGenomics, Inc. : June 22, 2017
finance.yahoo.com - June 23 at 8:22 AM |
| $63.13 Million in Sales Expected for NeoGenomics, Inc. (NEO) This Quarter
www.americanbankingnews.com - June 16 at 3:30 PM |
| Zacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Post Earnings of $0.02 Per Share
www.americanbankingnews.com - June 14 at 2:04 PM |
| NeoGenomics, Inc. (NEO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 10:51 PM |
| ETFs with exposure to NeoGenomics, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 7:41 PM |
| Steven A. Ross Sells 70,833 Shares of NeoGenomics, Inc. (NEO) Stock
www.americanbankingnews.com - June 6 at 7:50 PM |
| NeoGenomics, Inc. :NEO-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 7:29 PM |
| NeoGenomics, Inc. breached its 50 day moving average in a Bullish Manner : NEO-US : June 5, 2017
finance.yahoo.com - June 5 at 8:59 AM |
| NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests
finance.yahoo.com - June 2 at 8:09 PM |
| Form 4 NEOGENOMICS INC For: May 25 Filed by: TETRAULT LYNN A.
www.streetinsider.com - May 31 at 9:46 AM |
| NeoGenomics, Inc. (NEO) VP Sells $25,005.00 in Stock
www.americanbankingnews.com - May 30 at 8:31 PM |
| BTIG Research Reiterates "Buy" Rating for NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - May 28 at 7:20 AM |
| NeoGenomics, Inc. (NEO) Given a $11.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 27 at 9:34 AM |
| NeoGenomics, Inc. (NEO) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 11:06 PM |
| NeoGenomics, Inc. (NEO) Expected to Announce Earnings of $0.02 Per Share
www.americanbankingnews.com - May 17 at 4:16 PM |
| NeoGenomics Reports that its NeoLAB(R) Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer
finance.yahoo.com - May 15 at 10:13 AM |
| NeoGenomics, Inc. (NEO) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 9 at 7:14 AM |
| NeoGenomics (NEO) Getting Somewhat Favorable News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 1:21 AM |
| NeoGenomics (NEO) Receiving Somewhat Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 30 at 3:27 PM |
| NeoGenomics, Inc. (NEO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 28 at 8:00 PM |
| NeoGenomics, Inc. (NEO) Expected to Post Quarterly Sales of $65.99 Million
www.americanbankingnews.com - April 28 at 1:16 PM |
NeoGenomics (NEO) Chart for Wednesday, August, 16, 2017
